Elevations in Circulating 1, 25-Dihydroxyvitamin D in Three Patients with Lymphoma-Associated Hypercalcemia

128Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Three patients with hypercalcemia associated with malignant lymphoma and elevations in plasma 1, 25-dihydroxyvitamin D [1, 25-(OH)2D] are described. In addition to the elevation of circulating 1, 25-(OH)2D, these three patients were characterized by suppressed immunoreactive PTH levels and urinary cAMP excretion, elevated fasting urinary excretion of calcium, and absence of adenylate cyclase-stimulating activity in the tumor extracts. Bone marrow biopsy and skeletal radionuclide scans were negative for lymphoma in two patients. Surgical excision of a solitary splenic lymphoma in one patient and medical therapy in another patient resulted in rapid normalization of the serum calcium and plasma 1, 25-(OH)2D levels. These findings confirm an earlier observation that elevated plasma levels of 1, 25-(OH)2D may occur in certain patients with lymphoma and suggest that this vitamin D metabolite may act as a humoral or systemic mediator of hypercalcemia. Proof that this is the case and identification of the source of 1, 25-(OH)2D production will require further study. © 1985 by The Endocrine Society.

Cite

CITATION STYLE

APA

Rosenthal, N., Insogna, K. L., Godsall, J. W., Smaldone, L., Waldron, J. A., & Stewart, A. F. (1985). Elevations in Circulating 1, 25-Dihydroxyvitamin D in Three Patients with Lymphoma-Associated Hypercalcemia. Journal of Clinical Endocrinology and Metabolism, 60(1), 29–33. https://doi.org/10.1210/jcem-60-1-29

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free